eu efre logo

New Publication by A. Dityatev


The CBBS congratulates Alexander Dityatevs group, located at the German Center for Neurodegenerative Diseases (DZNE), on their latest publication in the Journal of Clinical Investigation.

The important study shows that a one-week treatment with a new inhibitor of matrix metalloproteinases can suppress epileptogenesis in a mouse model of the status epilepticus. Accure Therapeutics is bringing this drug into clinical trials - expected in 2022 - as a result of a collaboration between several academic groups and a biotech company funded by EU ITN ECMED.

Read more here.